/
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure.
The business is unprofitable at the operating level (-152.19% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 50.1% YoY. Margins deteriorated 114.1pp alongside, both lines moving the wrong way.
ROIC dropped from -36.21% to -39.71%, capital efficiency is deteriorating. Negative free cash flow of -$66M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$45M
▼ -50.1% YoY
Net Income (TTM)
-$44M
▼ -738.0% YoY
Op. Margin
-86.77%
▼ -114.1pp YoY
ROIC
-36.91%
▼ -3.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$59M
▼ -12.3% YoY
Op. Cash Flow (TTM)
-$59M
▼ -12.7% YoY
Net Debt
-$73M
Net Cash Position
Cash & Equiv.
$101M
5Y CAGR: +7.1%
Continue Research